Conclusions: Isolates were recovered from clinical specimens from 1985 to 2013. They were identified by standard methods\(^5\), \(^6\) match, within 8 clusters, especially those of cluster XIVa.

These data show that SMT is not active against some clostridia and might have a lesser impact

Discussion

Conclusions: These data show that SM19969's activity varied according to

Materials and Methods

Isolates were recovered from clinical specimens from 1985 to 2013. They were identified by standard methods\(^5\), \(^6\) match, within 8 clusters, especially those of cluster XIVa. Our current study extends these observations to 162 clostridia species —

Although SM19969's selective activity against fidaxomicin, vancomycin, and metronidazole, against gram positive and negative anaerobic species, has been well described, the effect of these drugs on the normal microbial flora and the impact of these drugs on the clinical course of CDI are not well understood. Therefore, the following evaluation by clinical trials seems warranted.

Acknowledgments

This study was supported by Summit plc.